Executive Committee

Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance

Retrieved on: 
Monday, April 1, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Letter, Chairperson, Executive Committee, TSX, OTCQX, Justice, Food

Antibe Therapeutics Inc. (“Antibe” or the “Company” TSX: ATE, OTCQX: ATBPF) today announced that it received verbal notice on the afternoon of March 28, 2024 from the U.S. Food and Drug Administration (“FDA”) that otenaproxesul has been placed on clinical hold, postponing the initiation of the planned Phase II trial.

Key Points: 
  • Antibe Therapeutics Inc. (“Antibe” or the “Company” TSX: ATE, OTCQX: ATBPF) today announced that it received verbal notice on the afternoon of March 28, 2024 from the U.S. Food and Drug Administration (“FDA”) that otenaproxesul has been placed on clinical hold, postponing the initiation of the planned Phase II trial.
  • Antibe expects to receive a formal Clinical Hold Letter from the FDA within 30 days outlining their rationale and further details.
  • Separately, the Company announced that Nuance Pharma Limited has commenced legal action in the Ontario Superior Court of Justice to seek recognition of and enforce the arbitration award in Ontario previously announced by Antibe in its press release of March 4, 2024.
  • Nuance Pharma is seeking the appointment of a receiver as part of its relief; a hearing date has not been set.

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Research, RLT, FAP, Ayala, NDA, Acquisition, Executive Committee, Spacecraft, PIPE, Phase 3, Pharmacology, ADC, Pharmaceutical industry

We expect to add novel antibody-drug conjugates (ADCs) and radioligand therapies (RLTs) to the pipeline through internal discovery efforts while continuing to evaluate opportunities to acquire high-quality assets on favorable financial terms.

Key Points: 
  • We expect to add novel antibody-drug conjugates (ADCs) and radioligand therapies (RLTs) to the pipeline through internal discovery efforts while continuing to evaluate opportunities to acquire high-quality assets on favorable financial terms.
  • Immunome expects to report topline data for the ongoing Phase 3 RINGSIDE Part B trial of AL102 in the first quarter of 2025.
  • In parallel, Immunome is evaluating and performing additional manufacturing and pharmacology work required to support an NDA submission of AL102.
  • Immunome reported a net loss of $106.8 million, or basic and diluted net loss per share attributable to common stockholders of $5.38, for the year ended December 31, 2023.

Pantheon announces leadership succession plan, Kathryn Leaf to become CEO in 2025

Retrieved on: 
Thursday, March 21, 2024
Professional Services, Business, Finance, Asset Management, Consulting, Banking, Real estate, KLFB, Type, Central bank, Growth, Private equity, Investment advisory, Partner (business rank), Partnership, Lead, History, Sale, LLP, Strategic planning, Real assets, Executive Committee, Pantheon Ventures, Investment, DAC, AUM, Money, Guernsey Financial Services Commission, Security (finance)

The transition will be effective from January 1, 2025, and is subject to standard regulatory approval.

Key Points: 
  • The transition will be effective from January 1, 2025, and is subject to standard regulatory approval.
  • I am very pleased that Kathryn will lead Pantheon through this next exciting phase of growth as we look to continue to deliver market-leading strategies to our investors.”
    Ms.
  • Leaf is a 25-year private markets investor and a 15-year veteran at Pantheon.
  • Pantheon Ventures (Guernsey) Ltd and a number of other Pantheon entities incorporated in Guernsey are regulated by the Guernsey Financial Services Commission.

Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines

Retrieved on: 
Wednesday, March 20, 2024
Science, Other Science, Research, Pharmaceutical, Oncology, Health, Genetics, Other Health, CE, Thermo Fisher Scientific, CDX, Patient, NGS, Bayer, Executive Committee, Neoplasm, Liquid biopsy, Pharmaceutical industry

Bayer AG and Thermo Fisher Scientific Inc. today announced to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together.

Key Points: 
  • Bayer AG and Thermo Fisher Scientific Inc. today announced to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together.
  • These will help identify patients who may benefit from Bayer’s growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time.
  • Pairing this with Bayer’s growing precision oncology portfolio, we are well-positioned for the potential to help ensure that eligible patients can be quickly matched with the right treatment.”
    Financial terms of the cooperation were not disclosed.
  • *The Genexus Dx instrument and the Oncomine Dx Express Test are currently CE-IVD and are only available in countries that accept the CE mark.

Positive topline results from Phase III long-term study OASIS 3 support submissions for marketing authorization for Bayer’s elinzanetant

Retrieved on: 
Tuesday, March 19, 2024
Health, Fitness & Nutrition, Clinical Trials, Research, Pharmaceutical, Science, International Menopause Society, VMS, Menopause, OASIS, Executive Committee, Imperial College London, Woman, Hot, Safety, Elinzanetant, Phase, Marketing, Pharmaceutical industry

Bayer today announced positive topline results of the Phase III study OASIS 3 evaluating the efficacy and long-term safety of the investigational compound elinzanetant versus placebo.

Key Points: 
  • Bayer today announced positive topline results of the Phase III study OASIS 3 evaluating the efficacy and long-term safety of the investigational compound elinzanetant versus placebo.
  • The long-term safety profile observed over 52 weeks in the OASIS 3 study is overall consistent with previously conducted studies and published data1,2 on elinzanetant.
  • “OASIS 3 was designed to address the important question of the long-term profile of elinzanetant.
  • “These results, coupled with the recent announcement of topline data for OASIS 1 and OASIS 2, strengthen our confidence in the proposed efficacy and safety of elinzanetant as a potential novel non-hormonal solution for women experiencing menopause-related symptoms.”
    OASIS 3 (NCT05030584) is the third Phase III study in the OASIS clinical development program with positive topline results.

Bayer and Thermo Fisher Scientific Collaborate to Increase Patient Access to Precision Cancer Medicines

Retrieved on: 
Wednesday, March 20, 2024
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, CE, Thermo Fisher Scientific, CDX, Patient, NGS, Bayer, Executive Committee, Neoplasm, Liquid biopsy, Pharmaceutical industry

Bayer AG and Thermo Fisher Scientific Inc. today announced a collaboration to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together.

Key Points: 
  • Bayer AG and Thermo Fisher Scientific Inc. today announced a collaboration to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together.
  • These will help identify patients who may benefit from Bayer’s growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time.
  • Pairing this with Bayer’s growing precision oncology portfolio, we are well-positioned for the potential to help ensure that eligible patients can be quickly matched with the right treatment.”
    Financial terms of the cooperation were not disclosed.
  • *The Genexus Dx instrument and the Oncomine Dx Express Test are currently CE-IVD and are only available in countries that accept the CE mark.

World-Renowned Ancient DNA Expert, HHMI Investigator, and MacArthur Award Winner Beth Shapiro, Ph.D., Joins Colossal as Chief Science Officer

Retrieved on: 
Tuesday, March 19, 2024
Environment, Research, Genetics, Environmental Issues, Environmental Health, Biotechnology, Health, Other Science, Science, Genomics, Gene, Executive Committee, National Geographic Explorer, Woolly mammoth, Cell, University, Pennsylvania State University, Television, Life, DNA, Stanford University, CRISPR, Ice, Vertebrate Genomes Project, Hologenomics, Genome, HHMI, Colossal Biosciences, Balliol College, Oxford, Howard Hughes Medical Institute, Ecology and Evolutionary Biology, CSO, Domestication, Natural history, National academy, American Academy, Biology, Searle, George Church, Multimedia, MacArthur Fellows Program, Hunting

Colossal Biosciences, the world’s first de-extinction company, today announced that Beth Shapiro, Ph.D. , internationally renowned evolutionary molecular biologist, leader in paleogenomics, and ancient DNA expert, has joined as Chief Science Officer.

Key Points: 
  • Colossal Biosciences, the world’s first de-extinction company, today announced that Beth Shapiro, Ph.D. , internationally renowned evolutionary molecular biologist, leader in paleogenomics, and ancient DNA expert, has joined as Chief Science Officer.
  • In this role, she will oversee the continued expansion of the company’s de-extinction and conservation science teams.
  • A MacArthur “Genius Grant” Award winner and National Geographic Explorer, Beth Shapiro is a pioneer in the scientific fields of ancient DNA and paleogenomics.
  • “She’s the author of inspiring books 'How to Clone a Mammoth' and 'Life as We Made It,' plus an HHMI and MacArthur Fellow.

Nomura Introduces Nomura Capital Management as Firm Refines Focus on Investment Management Business in the Americas

Retrieved on: 
Monday, March 11, 2024
Banking, Professional Services, Finance, CIO, NHA, International finance, Investment management, Growth, Nomura Holdings, Entrepreneurship, NPC, Head, Executive Committee, NCM, Senior, NAM, Credit, Investment, Financial services

Nomura Holdings, Inc has realigned the firm’s collective asset and investment management capabilities in the Americas under the new brand Nomura Capital Management LLC (NCM).

Key Points: 
  • Nomura Holdings, Inc has realigned the firm’s collective asset and investment management capabilities in the Americas under the new brand Nomura Capital Management LLC (NCM).
  • NCM reflects an ongoing commitment to increase the impact of its investment management business to the overall results of Nomura Group.
  • The firm expects the consolidated go-to-market approach of NCM will play a vital part of Nomura Group’s growth strategy as its investment management business expands both in the Americas and globally.
  • Backed by Nomura, a century-old global financial services institution, Nomura Capital Management plays a vital part of Nomura Group’s growth strategy as its investment management business expands both in the Americas and globally.

IAAO Selects Amy Rasmussen as Executive Director

Retrieved on: 
Wednesday, April 3, 2024
RES, Drake University, AAS, Iowa State University, Public policy, Research, Committee, Executive Committee, Riverside County, California, Psychology, Finance, Management

KANSAS CITY, Mo., April 3, 2024 /PRNewswire/ -- Following a nationwide search by the IAAO Executive Director Search Task Force, Amy Rasmussen, RES, AAS, FIAAO, was selected by the Board to serve as the new IAAO Executive Director and joined the organization on April 1.

Key Points: 
  • KANSAS CITY, Mo., April 3, 2024 /PRNewswire/ -- Following a nationwide search by the IAAO Executive Director Search Task Force, Amy Rasmussen, RES, AAS, FIAAO, was selected by the Board to serve as the new IAAO Executive Director and joined the organization on April 1.
  • Ms. Rasmussen served on the IAAO Board as a director and on the Executive Committee as Immediate Past President, President, President-Elect, and Vice President.
  • She has achieved the IAAO Assessment Administration Specialist (AAS) and Residential Evaluation Specialist (RES) designations; was selected as an IAAO Fellow (FIAAO); and has been an IAAO Senior Instructor since 2016.
  • IAAO is the leading nonprofit, educational and research association for individuals in the assessment profession and others with an interest in property valuation and taxation.

PKF O'Connor Davies' Laura K. Barooshian Receives 2024 Excellence Award from Boston Estate Planning Council

Retrieved on: 
Tuesday, April 2, 2024
Certified Public Accountant, Bentley University, BEPC, Baker Center, Executive Committee, Estate, Partner, Leadership Council, PKF

NEW YORK, April 2, 2024 /PRNewswire-PRWeb/ -- PKF O'Connor Davies, one of the nation's largest accounting, tax and advisory practices, is proud to announce that Laura K. Barooshian, a Partner in the organization's Private Client Services group and a Member of the organization's Executive Committee, has been named the recipient of the Boston Estate Planning Council's (BEPC) 2024 Excellence Award. The annual award recognizes professional excellence in estate planning as well as the honoree's contributions to the Boston community.

Key Points: 
  • The annual award recognizes professional excellence in estate planning as well as the honoree's contributions to the Boston community.
  • "Through professional excellence and community stewardship, Laura has distinguished herself as one of the leading estate planners in the Boston region," said Laurie J. Austin, New England Co-Managing Partner at PKF O'Connor Davies.
  • "Through professional excellence and community stewardship, Laura has distinguished herself as one of the leading estate planners in the Boston region," said Laurie J. Austin, New England Co-Managing Partner at PKF O'Connor Davies.
  • Barooshian will be honored during the BEPC's 2024 Annual Gala on May 16, 2024.